149 related articles for article (PubMed ID: 7566280)
1. The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease.
van Herwaarden CL; Bast A; Dekhuijzen PN
Neth J Med; 1995 Aug; 47(2):45-8. PubMed ID: 7566280
[No Abstract] [Full Text] [Related]
2. [Bronchial mucus modifiers, antioxidants and antiproteases].
Polu JM; Chabot F; Wallaert B
Rev Mal Respir; 1993; 10(2):87-100. PubMed ID: 8502804
[No Abstract] [Full Text] [Related]
3. Preventing exacerbations of chronic bronchitis and COPD.
Ekberg-Jansson A; Larsson S; Löfdahl CG
BMJ; 2001 May; 322(7297):1259-61. PubMed ID: 11375214
[No Abstract] [Full Text] [Related]
4. Aerosolized detergents and mucolytic agents in the treatment of stable chronic obstructive pulmonary disease.
Barton AD
Am Rev Respir Dis; 1974 Dec; 110(6 Pt 2):104-10. PubMed ID: 4613216
[No Abstract] [Full Text] [Related]
5. [Usefulness of mucoactive drugs in respiratory diseases].
Serrano J; Sanchis J
Arch Bronconeumol; 1998 Jan; 34(1):28-35. PubMed ID: 9522017
[No Abstract] [Full Text] [Related]
6. [Cell oxidative processes and antioxidant mucoactive drugs].
González-Mangado N; Morera Prat J
Arch Bronconeumol; 2001 Nov; 37(10):407-10. PubMed ID: 11734120
[No Abstract] [Full Text] [Related]
7. Methods of evaluation of expectorants and mucolytics--measurement of lung function.
Bake B
Eur J Respir Dis Suppl; 1980; 110():209-16. PubMed ID: 6938384
[No Abstract] [Full Text] [Related]
8. From mucolytic to antioxidant and liver protection: new aspects in the intensive care unit career of N-acetylcysteine.
Kiefer P; Vogt J; Radermacher P
Crit Care Med; 2000 Dec; 28(12):3935-6. PubMed ID: 11153640
[No Abstract] [Full Text] [Related]
9. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
10. [Antioxidants support the intrinsic physical response. Interview by Heinz W. Weismann].
Magnussen H
Pneumologie; 1996 Jan; 50(1):VII. PubMed ID: 8774929
[No Abstract] [Full Text] [Related]
11. [Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness].
Gillissen A
Pneumologie; 2011 Sep; 65(9):549-57. PubMed ID: 21761386
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic agents.
Aspen Emphysema Conf; 1965; 8():35-8. PubMed ID: 5900088
[No Abstract] [Full Text] [Related]
13. Chronic obstructive pulmonary disease.
Wynne JW
Compr Ther; 1975 Dec; 1(8):26-30. PubMed ID: 1222557
[TBL] [Abstract][Full Text] [Related]
14. Acute exacerbations of chronic obstructive pulmonary disease.
Stey C
Ann Intern Med; 2002 Apr; 136(7):556-8; author reply 556-8. PubMed ID: 11926798
[No Abstract] [Full Text] [Related]
15. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
[TBL] [Abstract][Full Text] [Related]
16. [New perspectives of antioxidant therapy with thiols: nacystelyn].
Gillissen A
Pneumologie; 1996 Dec; 50 Suppl 3():834-7. PubMed ID: 9157438
[No Abstract] [Full Text] [Related]
17. N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer.
van Zandwijk N
J Cell Biochem Suppl; 1995; 22():24-32. PubMed ID: 8538205
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine -- passe-partout or much ado about nothing?
Aitio ML
Br J Clin Pharmacol; 2006 Jan; 61(1):5-15. PubMed ID: 16390346
[TBL] [Abstract][Full Text] [Related]
19. [What is assured in therapy with expectorants?].
Schlegel J; Ferlinz R
Internist (Berl); 1989 Dec; 30(12):805-9. PubMed ID: 2695490
[No Abstract] [Full Text] [Related]
20. [The application of N-acetylcysteine in optimization of specific pharmacological therapies].
Hołyńska-Iwan I; Wróblewski M; Olszewska-Słonina D; Tyrakowski T
Pol Merkur Lekarski; 2017 Sep; 43(255):140-144. PubMed ID: 28987048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
